PR Newswire BiotechOriginal article
Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction
Phase 2positiveCBL-514Positive
AI Analysis
Summary
Caliway announced positive Phase 2 results for CBL-514 in Dercum's Disease, achieving the primary endpoint with statistically significant and sustained pain reduction compared to placebo. The company is exploring expansion opportunities for CBL-514 beyond Dercum's Disease.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Primary endpoint achieved with statistically significant pain reduction across FAS and PP populations compared with placebo
Importance:7/10
Sentiment:
0.85
Phase 2positive dataprimary endpoint metpain reductionDercum's DiseaseCBL-514
Read the original article
Published by PR Newswire Biotech on September 23, 2026 2:08 AM